Drugs for Interstitial Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 169)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bosentan |
Approved, Investigational |
Phase 4,Phase 2,Phase 3 |
|
147536-97-8 |
104865
|
Synonyms:
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
bosentan
Bosentan
bosentán
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
bosentanum
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
|
D07538
DB00559
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
PDSP1_001731
PDSP2_001714
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
|
|
2 |
|
Iloprost |
Approved, Investigational |
Phase 4,Phase 2,Phase 3 |
|
78919-13-8 |
6443959
|
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
[3H]-Iloprost
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
|
CID9975807
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
Ilomedin
Ilomedine
Iloprost
ILOPROST
Iloprost (INN)
Iloprost [BAN:INN]
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
|
|
3 |
|
Menthol |
Approved |
Phase 4 |
|
2216-51-5 |
16666
|
Synonyms:
(−
(-)-(1R,3R,4S)-Menthol
(-)-menthol
()-Menthol
(-)-Menthyl alcohol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1R)-(-)-Menthol
(1r,2s,5r)-(-)-menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(L)-MENTHOL
(r)-(-)-menthol
(R)-(-)-Menthol
)-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
1-Menthol
20747-49-3
2216-51-5
2-Isopropyl-5-methylcyclohexanol
3-p-Menthol
491-02-1
4-Isopropyl-1-methylcyclohexan-3-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
5-Methyl-2-(1-methylethyl)cyclohexanol
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
Caswell No. 540
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
D-(-)-Menthol
d,l-Menthol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
d-Menthol
d-Neomenthol
D-p-Menthan-3-ol
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
|
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
Headache crystals
Hexahydrothymol
HMS1922G13
HMS2092L14
HMS502I22
HSDB 5662
HSDB 593
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
l-(-)-Menthol
L-(-)-menthol
L-(-)-Menthol
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
l-Menthol
L-menthol
L-Menthol
l-Menthol (JP15)
l-Menthol (natural)
l-Menthol (TN)
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
M0321
M0545
M2772_SIAL
Menthacamphor
Menthol
MENTHOL
--MENTHOL
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MLS002207256
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
nchembio862-comp1
NCI-C50000
Neoisomenthol
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Peppermint camphor
p-Menthan-3-ol
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
RACEMIC MENTHOL U.S.P.
rac-Menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
Spectrum_000305
SPECTRUM1503134
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
STK802468
Tra-kill tracheal mite killer
U.S.p. Menthol
U.S.P. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
|
|
4 |
|
Gefitinib |
Approved, Investigational |
Phase 4,Phase 3 |
|
184475-35-2 |
123631
|
Synonyms:
184475-35-2
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
gefitinib
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
|
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
nchembio.117-comp18
nchembio866-comp14
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZINC19632614
|
|
5 |
|
Pirfenidone |
Approved, Investigational |
Phase 4,Phase 2 |
|
53179-13-8 |
40632
|
Synonyms:
5-21-07-00197 (Beilstein Handbook Reference)
53179-13-8
5-Methyl-1-phenyl-1H-pyridin-2-one
5-Methyl-1-phenyl-2(1H)-pyridone
5-Methyl-1-phenyl-2-(1H)-pyridone
5-methyl-1-phenylpyridin-2(1H)-one
5-methyl-1-phenylpyridin-2-one
AC1L2454
AC-6797
AMR 69
AMR-69
Bio1_000397
Bio1_000886
Bio1_001375
BRD-K96862998-001-03-1
BRN 1526549
C093844
C12H11NO
CID40632
D01583
Deskar
EN000704
Esbriet
EU-0100907
F-647
FT-0082541
I01-1466
|
KS-5041
Lopac0_000907
Lopac-P-2116
LS-133834
MLS000860042
NCGC00015806-01
NCGC00015806-03
NCGC00015806-05
NCGC00024992-01
NCGC00024992-02
NCGC00024992-03
P 2116
P2116_SIGMA
Pirespa
Pirfenidona
Pirfenidona [INN-Spanish]
PIRFENIDONE
Pirfenidone (Deskar)
Pirfenidone (JAN/USAN/INN)
Pirfenidone [USAN:INN]
Pirfenidonum
Pirfenidonum [INN-Latin]
S-7701
SMR000326900
Tocris-1093
ZINC00001958
|
|
6 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206
|
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
Bax 3084
BRN 2041023
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
|
MolPort-001-775-746
MR_6S4
MR6S4
NCGC00167421-01
PC4681
Sevofluran
sevoflurane
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
Ultane
Ultane (TN)
UNII-38LVP0K73A
ZINC01530810
|
|
7 |
|
Morphine |
Approved, Investigational |
Phase 4 |
|
57-27-2 |
5288826
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
HSDB 2134
Infumorph
|
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
|
|
8 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4,Early Phase 1 |
|
83-43-2 |
6741
|
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6-Methylprednisolone
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medrol
Medrol (TN)
|
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
|
|
9 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4,Early Phase 1 |
|
50-24-8 |
5755
|
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di Adreson F
Di-adreson F
Di-Adreson F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
|
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
|
|
10 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311
|
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
|
Citrate
Citretten
Citric acid
Citric Acid, Anhydrous
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
|
|
11 |
|
Antihypertensive Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
12 |
|
Endothelin Receptor Antagonists |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
13 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4,Phase 3 |
|
|
|
14 |
|
Phosphodiesterase Inhibitors |
|
Phase 4,Phase 3 |
|
|
|
15 |
|
Sildenafil Citrate |
|
Phase 4 |
|
171599-83-0 |
|
16 |
|
Vasodilator Agents |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
17 |
|
Platelet Aggregation Inhibitors |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
18 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 3,Phase 2,Early Phase 1 |
|
|
|
19 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4,Phase 3,Early Phase 1 |
|
|
|
20 |
|
glucocorticoids |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
21 |
|
Hormone Antagonists |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
22 |
|
Hormones |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
23 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 |
|
|
|
24 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
25 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
26 |
|
Anesthetics |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
27 |
|
Central Nervous System Depressants |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
28 |
|
Analgesics |
|
Phase 4,Phase 2 |
|
|
|
29 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 |
|
|
|
30 |
|
Autonomic Agents |
|
Phase 4,Phase 1,Early Phase 1 |
|
|
|
31 |
|
Protective Agents |
|
Phase 4,Phase 2,Phase 3,Early Phase 1 |
|
|
|
32 |
|
Analgesics, Non-Narcotic |
|
Phase 4,Phase 2 |
|
|
|
33 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4,Phase 2 |
|
|
|
34 |
|
Anesthetics, General |
|
Phase 4,Phase 1 |
|
|
|
35 |
|
Anesthetics, Inhalation |
|
Phase 4,Phase 1 |
|
|
|
36 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
37 |
|
Narcotics |
|
Phase 4 |
|
|
|
38 |
|
Antiemetics |
|
Phase 4,Early Phase 1 |
|
|
|
39 |
|
Gastrointestinal Agents |
|
Phase 4,Early Phase 1 |
|
|
|
40 |
|
Methylprednisolone acetate |
|
Phase 4,Early Phase 1 |
|
|
|
41 |
|
Methylprednisolone Hemisuccinate |
|
Phase 4,Early Phase 1 |
|
|
|
42 |
|
Neuroprotective Agents |
|
Phase 4,Early Phase 1 |
|
|
|
43 |
|
Prednisolone acetate |
|
Phase 4,Early Phase 1 |
|
|
|
44 |
|
Prednisolone hemisuccinate |
|
Phase 4,Early Phase 1 |
|
|
|
45 |
|
Prednisolone phosphate |
|
Phase 4,Early Phase 1 |
|
|
|
46 |
|
Citrate |
Nutraceutical |
Phase 4 |
|
|
|
47 |
|
Calamus |
Nutraceutical |
Phase 4 |
|
|
|
48 |
|
Treprostinil |
Approved, Investigational |
Phase 3,Phase 2 |
|
81846-19-7 |
6918140
54786
|
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
|
LRX 15
LS-177654
LS-187014
LS-187645
Remodulin (TN)
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil sodium
treprostinilo
Treprostinilo
treprostinilum
Treprostinilum
U 62840
U-62,840
UNII-RUM6K67ESG
Uniprost
UT-15
Viveta
|
|
49 |
|
Minocycline |
Approved, Investigational |
Phase 3 |
|
10118-90-8 |
5281021
|
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
Bio-0062
Borymycin
BRN 3077644
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
Lactoferrin B & Minocycline
|
Lactoferrin H & Minocycline
LMPK07000002
LS-93850
MINO
Minociclina
Minociclina [INN-Spanish]
minociclinum
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
minocycline
Minocycline (USAN/INN)
Minocycline [USAN:BAN:INN]
Minocycline HCl
Minocycline Monohydrochloride
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
MIY
NCGC00178854-01
nchembio.559-comp1
Novo-Minocycline
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
|
|
50 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3,Phase 2 |
|
50-18-0, 6055-19-2 |
2907
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
|
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
Interventional clinical trials:
(show top 50)
(show all 245)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study |
Unknown status |
NCT00637065
|
Phase 4 |
Bosentan;Placebo |
2 |
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil |
Unknown status |
NCT00625079
|
Phase 4 |
sildenafil;sildenafil |
3 |
Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) |
Unknown status |
NCT02286063
|
Phase 4 |
Ambulatory Oxygen |
4 |
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan |
Unknown status |
NCT00625469
|
Phase 4 |
bosentan |
5 |
Pulmonary Rehabilitation in Interstitial Lung Diseases |
Completed |
NCT00882817
|
Phase 4 |
|
6 |
Iressa Case Control Study in Japan |
Completed |
NCT00252759
|
Phase 4 |
|
7 |
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension |
Completed |
NCT00403650
|
Phase 4 |
Iloprost |
8 |
Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep |
Recruiting |
NCT02150616
|
Phase 4 |
Oxygen;Sham oxygen (room air) |
9 |
Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance |
Recruiting |
NCT02143687
|
Phase 4 |
Oxygen;Sham oxygen (room air) |
10 |
Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease |
Recruiting |
NCT02622022
|
Phase 4 |
Morphine hydrochloride |
11 |
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis |
Recruiting |
NCT03265405
|
Phase 4 |
Low dose prednisolone;Medium dose prednisolone |
12 |
Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis |
Not yet recruiting |
NCT02821689
|
Phase 4 |
Pirfenidone |
13 |
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension |
Unknown status |
NCT00705133
|
Phase 3 |
treprostinil |
14 |
Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection |
Unknown status |
NCT00841750
|
Phase 3 |
|
15 |
Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study |
Unknown status |
NCT00203697
|
Phase 3 |
minocycline |
16 |
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis |
Unknown status |
NCT00439543
|
Phase 2, Phase 3 |
Iloprost inhalation |
17 |
Open-label Study With Bosentan in Interstitial Lung Disease |
Completed |
NCT00319033
|
Phase 2, Phase 3 |
bosentan |
18 |
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma |
Completed |
NCT01553981
|
Phase 3 |
Tadalafil;Placebo |
19 |
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma |
Completed |
NCT00070590
|
Phase 2, Phase 3 |
Bosentan |
20 |
BUILD 3: Bosentan Use in Interstitial Lung Disease |
Completed |
NCT00391443
|
Phase 3 |
Bosentan;Placebo |
21 |
Rituximab in Rheumatoid Arthritis Lung Disease |
Completed |
NCT00578565
|
Phase 3 |
Rituximab |
22 |
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer |
Completed |
NCT01404260
|
Phase 3 |
Gefitinib;Gemcitabine +Carboplatin |
23 |
A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy |
Completed |
NCT01955824
|
Phase 2, Phase 3 |
1% lignocaine;2% lignocaine |
24 |
Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis |
Completed |
NCT00071461
|
Phase 2, Phase 3 |
bosentan;Placebo |
25 |
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study |
Completed |
NCT00131274
|
Phase 2, Phase 3 |
Imatinib Mesylate (Gleevec) |
26 |
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 |
Completed |
NCT00631475
|
Phase 3 |
Bosentan |
27 |
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease |
Recruiting |
NCT01570764
|
Phase 3 |
Cyclophosphamide;Placebo |
28 |
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) |
Recruiting |
NCT02999178
|
Phase 3 |
Nintedanib;Placebo |
29 |
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease |
Recruiting |
NCT02896205
|
Phase 3 |
Mycophenolate mofetil;Placebo |
30 |
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases |
Recruiting |
NCT02990286
|
Phase 3 |
Rituximab;Placebo of Rituximab;Mycophenolate Mofetil |
31 |
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD |
Recruiting |
NCT01862926
|
Phase 2, Phase 3 |
Rituximab;Cyclophosphamide |
32 |
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. |
Recruiting |
NCT03313180
|
Phase 3 |
Nintedanib |
33 |
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE |
Recruiting |
NCT02630316
|
Phase 2, Phase 3 |
Inhaled Treprostinil;Placebo |
34 |
Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease |
Recruiting |
NCT03241420
|
Phase 3 |
|
35 |
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis |
Active, not recruiting |
NCT02597933
|
Phase 3 |
Nintedanib;Placebo |
36 |
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC |
Active, not recruiting |
NCT02474355
|
Phase 3 |
AZD9291 Dosing |
37 |
Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization |
Active, not recruiting |
NCT01973998
|
Phase 3 |
Roflumilast;Placebo |
38 |
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE |
Enrolling by invitation |
NCT02633293
|
Phase 2, Phase 3 |
Inhaled Treprostinil |
39 |
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score |
Not yet recruiting |
NCT03386539
|
Phase 3 |
Everolimus;Tacrolimus;Mycophenolate Mofetil |
40 |
A Clinical Trial for CTD-ILD Treatment |
Terminated |
NCT01424033
|
Phase 2, Phase 3 |
N-Acetylcysteine |
41 |
Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure |
Terminated |
NCT03262571
|
Phase 3 |
|
42 |
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF |
Terminated |
NCT00768300
|
Phase 3 |
Ambrisentan;Placebo |
43 |
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases |
Terminated |
NCT01257802
|
Phase 3 |
depot leuprolide acetate 3.75 mg;Placebo |
44 |
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease |
Unknown status |
NCT01450644
|
Phase 2 |
|
45 |
Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air |
Unknown status |
NCT01140685
|
Phase 2 |
|
46 |
Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease |
Completed |
NCT02594839
|
Phase 1, Phase 2 |
Bone marrow mesenchymal stem cells;Placebo |
47 |
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) |
Completed |
NCT00883129
|
Phase 2 |
Mycophenolate mofetil;Cyclophosphamide;Placebo |
48 |
Ambulatory Oxygen for ILD |
Completed |
NCT01906931
|
Phase 2 |
|
49 |
Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) |
Completed |
NCT01933334
|
Phase 2 |
Pirfenidone |
50 |
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease |
Completed |
NCT01559129
|
Phase 2 |
Pomalidomide (CC-4047);Placebo |
|